Brain 17 Vienna

07.11.2017

Summary

Reactions

• Substantial step forward & paradigm change

• Introduction of molecular parameters • Challenge molecular marker testing!

• Associated changes of diagnostic format • Integrated diagnoses (CAVE time delay to molecular results)

• Greatest impact on diffuse gliomas & embryonal tumors

• More objective and precisely defined entities for enhanced patient management

43

44

Asking neuropathologists in 2016 post WHO

Outlook next WHO classification

• Diffuse gliomas • WHO grading system will be revised

• Pediatric low-grade gliomas • Integrated diagnoses will be introduced, e.g., for BRAF gene fusion in pilocytic astrocytomas

11 th European Congress of Neuropathology, Bordeaux, France

Aim: Assessing practice patterns regarding adult diffuse glioma during times of transition

• Ependymoma • WHO grading will be revised

• Whichmolecular markers have already been incorporated in routine practice

• Whichmolecular techniques are in daily use or will be implemented in the near future

• Set a baseline for future assessments

• Meningioma • WHO grading will be revised • DNA methylation profiling might be introduced (?)

Methods: Structured survey distributed onsite and among Euro-CNS members

46

45

130 Respondents from 40 countries

1. How would you rate the relevance of molecular marker testing in diagnostic neuropathology?

Very important Important Something to consider Not important

0 25 50 75 100 %

2. Do you currently use molecular information for diagnostic purposes? 3. Do you use „oligoastrocytoma“ as histological diagnosis?

• 93.8 % indicate to work as (neuro- )pathologist • 75 % report to work within Europe • Single respondents from 17 different countries (in red)

No of respondents 0 1

2-4 5-14 15+

%

0 25 50 75 100

Yes Occasionally No

Woehreretal,ClinNeuropathol2017

Woehreretal,ClinNeuropathol2017

47

48

8